A new resource roundup from the West Health Accelerator at the AHA’s Health Research & Educational Trust highlights five practical approaches across electronic health record optimization, virtual care and artificial intelligence utilization and integration.
Innovation
UCHealth’s Memorial Hospital Central and Memorial Hospital North in Colorado Springs are the first hospitals in Colorado to use the i-STAT Alinity traumatic brain injury blood test, a new tool that helps emergency physicians quickly determine whether adults may have suffered a mild brain injury,…
Hospital care for people with Parkinson’s disease costs nearly $8 billion annually and places about one in six hospitalized patients at significant risk for an avoidable complication due to healthcare systems that are not designed to meet their unique, time-sensitive needs.
Children’s Hospital Colorado helped the National Alliance of Sickle Cell Centers develop new national standards to improve how developmental and cognitive challenges are identified and managed in people with sickle cell disease (SCD).
A 16-year-old Kansas patient is looking toward a future with fewer health limitations after receiving a heart transplant at Children’s Mercy Kansas City.
In this conversation, Caroline DeLongchamps, director of the patient-and family-centered care program at MUSC Health, shares her powerful personal story and explains how patient and family-centered care can improve quality, strengthen trust, and transform how care is designed and delivered.
The American Hospital Association input on the FDA report on the risks and benefits to health and safety that are associated with non-device software as required under Section 3060 of the 21st Century Cures Act.
When a child is diagnosed with a serious illness, parents are faced with a tsunami of emotions, information, choices — and stress. One researcher at UVA Health Children's has found a way to communicate complicated information to parents: Paint them a picture.
CD19-positive mixed phenotype acute leukemia (MPAL) is one of the rarest forms of blood cancer. It’s also one of the deadliest; the median survival rate is usually months. And there has been no FDA-approved treatment — until now.
A gene therapy called LYFGENIA is transforming the way sickle cell disease is treated in children — but it isn’t easy to administer, and it’s not yet widely available.